Pediatric anemia: a growing concern with multifaceted causes and emerging treatments

Pediatric anemia remains a significant global health burden, affecting nearly half of children under the age of five. The World Health Organization estimates that almost two billion people worldwide suffer from anemia, with infants and young children disproportionately affected. Iron deficiency is the most common cause, followed by hemoglobinopathies, infections, and chronic diseases. Anemia in children often leads to increased morbidity, such as neurodevelopmental delays, poor growth, and a higher susceptibility to infections. Early identification and treatment are critical to mitigating these adverse outcomes.

The diagnostic approach to anemia in pediatric patients combines history, physical examination, and a detailed laboratory workup. Hemoglobin levels, mean corpuscular volume (MCV), and peripheral blood smears are essential initial tests. A classification based on MCV categorizes anemia as microcytic, normocytic, or macrocytic, further guiding the diagnostic pathway. Advances in genetic testing have allowed more precise diagnoses of inherited anemias, providing insights into previously unexplained cases.

Therapeutic strategies for pediatric anemia depend on the underlying cause. Nutritional approaches, including iron supplementation and fortified diets, are widely used for treating iron deficiency. Inherited anemias, such as thalassemia and sickle cell disease, may require more advanced treatments, including blood transfusions and, in severe cases, gene therapy. Emerging pharmacological treatments and gene-based therapies offer hope for complex and refractory cases. As understanding of pediatric anemia grows, the development of targeted therapies is expected to significantly improve patient outcomes.